Pharma Competitor Intelligence Explorer​ (AI Agent)

What is the Pharma Competitor Intelligence (CI) Explorer?

The Pharma Competitor Intelligence Explorer AI Agent helps users quickly survey and monitor originator drugs to support strategic decision-making across product development, licensing, and market entry planning.

Trained on Synapse’s approved drug and patent data, this AI agent delivers detailed reports covering drug efficacy, intended use (e.g., dosage, route of administration), patent protection status, market exclusivity timelines, and regional approval data.

Who is it for?

This tool is designed for professionals in:

• Competitive Intelligence (CI)

• Business Development & Licensing

• R&D Project Management (Pharma, CROs, CDMOs)

• Intellectual Property Law

What does it help with?

• Identifying product launch, licensing, and R&D opportunities

• Understanding global patent status and exclusivity periods

• Supporting market entry assessments and strategy development

• Replacing the need for costly and time-consuming external consulting services

How does it work?

1. Input your question
    

   

   • Ask about a specific drug and its regional approval status.

   • The AI agent automatically parses the necessary elements from your question.

2. Builds the analysis path
   The agent assembles a multi-step intelligence workflow:

   a) Drug Information

   • Includes dosage, route of administration (ROA), approval time, and structure

   b) Patent Assessment

   • Identifies patents related to approval (e.g., Orange Book patents)

   • Evaluates blocking patents by the original developer

   • Reviews competitor activity and patent filings

   c) Patent Challenge Path

   • Assesses Paragraph IV challenges and patent statement implications

   d) Market Exclusivity Period

   • Analyzes exclusivity timelines that may impact launch

   e) Market Entry Assessment

   • Summarizes findings to identify potential entry points

3. Generates a summary table

   

4. Performs overall analysis and synthesis

5. Creates a final shareable report
    

   

Limitations

• Covers only approved drugs (no pipeline or pre-approval data)

• Does not include Canada or Australia

• Export functionality is not available